Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in barrett's esophagus and esophageal adenocarcinoma

Journal of Proteome Research

Volumn 7, Issue 5, 2008, Pages 1953-1962

  Breton, Jean ^a,b,c   Gage, Matthew C ^a   Hay, Alastair W ^a   Keen, Jeffrey N ^a   Wild, Christopher P ^a   Donnellan, Clare ^a   Findlay, John B C ^a   Hardie, Laura J ^a,d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CEA GRENOBLE   (France)

^c UNIV GRENOBLE ALPES   (France)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

AKR1B10; AKR1C2; Barrett's; Cathepsin d; Esophagus

Indexed keywords

ALDOKETOREDUCTASE 1B10; ALDOKETOREDUCTASE 1C2; BIOLOGICAL MARKER; CATHEPSIN D; MESSENGER RNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG; AKR1B10 PROTEIN, HUMAN; AKR1C2 PROTEIN, HUMAN; ALDEHYDE REDUCTASE; HYDROXYSTEROID DEHYDROGENASE; PROTEOME; TUMOR MARKER;

ARTICLE; BARRETT ESOPHAGUS; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MASS SPECTROMETRY; METAPLASIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADENOCARCINOMA; ESOPHAGUS TUMOR; GENETICS; METABOLISM; MOLECULAR GENETICS; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADENOCARCINOMA; ALDEHYDE REDUCTASE; BARRETT ESOPHAGUS; CATHEPSIN D; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ESOPHAGEAL NEOPLASMS; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PROGNOSIS; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 52049108091     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr7007835     Document Type: Article

References (59)

1. Brown, L. M. Epidemiology of alcohol-associated cancers. Alcohol 2005, 35, 161-168.
2. Bollschweiler, E.; Wolfgarten, E.; Gutschow, C.; Holscher, A. H. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001, 92, 549-555.
3. Wild, C. P.; Hardie, L. J. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 2003, 3, 676-684.
4. Shaheen, N. J. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005, 128, 1554-1566.
5. McManus, D. T.; Olaru, A.; Meltzer, S. J. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res. 2004, 64, 1561-1569.
6. Brabender, J.; Marjoram, P.; Salonga, D.; Metzger, R.; Schneider, P. M.; Park, J. M.; Schneider, S.; Holscher, A. H.; Yin, J.; Meltzer, S. J.; Danenberg, K. D.; Danenberg, P. V.; Lord, R. V. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene 2004, 23, 4780-4788.
7. Helm, J.; Enkemann, S. A.; Coppola, D.; Barthel, J. S.; Kelley, S. T.; Yeatman, T. J. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin. Cancer Res. 2005, 11, 2478-2485.
8. Wang, S.; Zhan, M.; Yin, J.; Abraham, J. M.; Mori, Y.; Sato, F.; Xu, Y.; Olaru, A.; Berki, A. T.; Li, H.; Schulmann, K.; Kan, T.; Hamilton, J. P.; Paun, B.; Yu, M. M.; Jin, Z.; Cheng, Y.; Ito, T.; Mantzur, C.; Greenwald, B. D.; Meltzer, S. J. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006, 25, 3346-3356.
9. Lin, J.; Lin, L.; Thomas, D. G.; Greenson, J. K.; Giordano, T. J.; Robinson, G. S.; Barve, R. A.; Weishaar, F. A.; Taylor, J. M.; Orringer, M. B.; Beer, D. G. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin. Cancer Res. 2004, 10, 5708-5716.
10. Soldes, O. S.; Kuick, R. D.; Thompson, I. A.; Hughes, S. J.; Orringer, M. B.; Iannettoni, M. D.; Hanash, S. M.; Beer, D. G. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br. J. Cancer 1999, 79, 595-603.
11. Chen, X.; Ding, Y.; Liu, C. G.; Mikhail, S.; Yang, C. S. Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Carcinogenesis 2002, 23, 123-130.
12. Chen, X.; Li, N.; Wang, S.; Wu, N.; Hong, J.; Jiao, X.; Krasna, M. J.; Beer, D. G.; Yang, C. S. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J. Natl. Cancer Inst. 2003, 95, 1053-1061.
13. Zhao, J.; Chang, A. C.; Li, C.; Shedden, K. A.; Thomas, D. G.; Misek, D. E.; Manoharan, A. P.; Giordano, T. J.; Beer, D. G.; Lubman, D. M. Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol. Cell. Proteomics 2007, 6, 987-999.
14. Pohler, E.; Craig, A. L.; Cotton, J.; Lawrie, L.; Dillon, J. F.; Ross, P.; Kernohan, N.; Hupp, T. R. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell. Proteomics 2004, 3, 534-547.
15. Stoner, G. D.; Kaighn, M. E.; Reddel, R. R.; Resau, J. H.; Bowman, D.; Naito, Z.; Matsukura, N.; You, M.; Galati, A. J.; Harris, C. C. Establishment and characterization of SV40 T-andgen immortalized human esophageal epithelial cells. Cancer Res. 1991, 51, 365-371.
16. Palanca-Wessels, M. C.; Barrett, M. T.; Galipeau, P. C; Rohrer, K. L.; Reid, B. J.; Rabinovitch, P. S. Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities. Gastroenterology 1998, 114, 295-304.
17. Palanca-Wessels, M. C.; Klingelhutz, A.; Reid, B. J.; Norwood, T. H.; Opheim, K. E.; Paulson, T. G.; Feng, Z.; Rabinovitch, P. S. Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis 2003, 24, 1183-1190.
18. Rockett, J. C.; Larkin, K.; Darnton, S. J.; Morris, A. G.; Matthews, H. R. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br. J. Cancer 1997, 75, 258-263.
19. Hara, A.; Matsuura, K.; Tamada, Y.; Sato, K.; Miyabe, Y.; Deyashiki, Y.; Ishida. N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreduc-tase of human colon cells. Biochem. J. 1996, 313, 373-376.
20. Verhoeckx, K. C.; Bijlsma, S.; de Groene, E. M.; Witkamp, R. F.; van der Greef Rodenburg, R. J. A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line. Proteomics 2004, 4, 1014-1028.
21. Donnellan, C. Gene expression in oesophageal cells following acid and bile exposure. MD Thesis, University of Leeds, Leeds, U.K., 2006, 272 p.
22. Chang, M. W.; Grillari, J.; Mayrhofer, C; Fortschegger, K.; Allmaier, G.; Marzban, G.; Katinger, H.; Voglauer, R. Comparison of early passage, senescent and hTERT immortalized endothelial cells. Exp. Cell Res. 2005, 309, 121-136.
23. Liaudet-Coopman, E.; Beaujouin, M.; Derocq, D.; Garcia, M.; Glondu-Lassis, M.; Laurent-Matha, V.; Prebois, C.; Rochefort, H.; Vignon, F. Cathepsin D: newly discovered functions of a longstanding aspartic protease in cancer and apoptosis. Cancer Lett. 2006, 237, 167-179.
24. Rochefort, H.; Garcia, M.; Glondu, M.; Laurent, V.; Liaudet, E.; Rey, J. M.; Roger, P. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin. Chim. Acta 2000, 291, 157-170.
25. Skrzydlewska, E.; Sulkowska, M.; Wincewicz, A.; Koda, M.; Sulkows- ki, S. Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer. World J. Gastroenterol. 2005, 11, 4225-4229.
26. Leto, G.; Tumminello, F. M.; Crescimanno, M.; Flandina, C.; Gebbia, N. Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin. Exp. Metastasis 2004, 21, 91-106.
27. Fukuda, M. E.; Iwadate, Y.; Machida, T.; Hiwasa, T.; Nimura, Y.; Nagai, Y.; Takiguchi, M.; Tanzawa, H.; Yamaura, A.; Seki, N. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005, 65, 5190-5194.
28. van der Stappen, J. W.; Williams, A. C; Maciewicz, R. A.; Paraskeva, C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int. J. Cancer 1996, 67, 547-554.
29. Bernstein, H.; Payne, C. M.; Kunke, K.; Crowley-Weber, C. L.; Waltmire, C. N.; Dvorakova, K.; Holubec, H.; Bernstein, C; Vaillancourt, R. R.; Raynes, D. A.; Guerriero, V.; Garewal, H. A proteomic study of resistance to deoxycholate-induced apoptosis. Carcinogenesis 2004, 25, 681-692.
30. Bernstein, H.; Bernstein, C.; Payne, C. M.; Dvorakova, K.; Garewal, H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 2005, 589, 47-65.
31. Nehra, D.; Howell, P.; Williams, C. P.; Pye, J. K.; Beynon, J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999, 44, 598-602.
32. Jolly, A. J.; Wild, C. P.; Hardie, L. J. Acid and bile salts induce DNA damage in human oesophageal cell lines. Mutagenesis 2004, 19, 319-324.
33. Huang, L. J.; Chen, S. X.; Huang, Y.; Luo, W. J.; Jiang, H. H.; Hu, Q. H.; Zhang, P. F.; Yi, H. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 2006, 54, 87-94.
34. Burczynski, M. E.; Lin, H. K.; Penning, T. M. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999, 59, 607-614.
35. Seike, K.; Murata, M.; Hirakawa, K.; Deyashiki, Y; Kawanishi, S. Oxidative DNA damage induced by benz[a] anthracene dihydrodi- ols in the presence of dihydrodiol dehydrogenase. Chem. Res. Toxicol. 2004, 17, 1445-1451.
36. Kazemi-Noureini, S.; Colonna-Romano, S.; Ziaee, A. A.; Malboobi, M. A.; Yazdanbod, M.; Setayeshgar, P.; Maresca, B, Differential gene expression between squamous cell carcinoma of esophageus and its normal epithelium; altered pattern of mal, akrlc2, and rablla expression. World J. Gastroenterol. 2004, 10, 1716-1721.
37. Wang, L. S.; Chow, K. C; Wu, Y. C; Lin, T. Y.; Li, W. Y. Inverse expression of dihydrodiol dehydrogenase and glutathione-S-transferase in patients with esophageal squamous cell carcinoma. Int. J. Cancer 2004, 111, 246-251.
38. Lou, H.; Du, S.; Ji, Q.; Stolz, A. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by NRF2. Mol. Pharmacol. 2006, 69, 1662-1672.
39. Penning, T. M.; Jin, Y.; Steckelbroeck, S.; Lanisnik Rizner, T.; Lewis, M. Structure function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol. Cell. Endocrinol. 2004, 215, 63-72.
40. Stolz, A.: Hammond, L.; Lou, H.; Takikawa, H.; Ronk, M.; Shively, J. E. cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family. J. Biol. Chem. 1993, 268, 10448-10457.
41. Deng, H. B.; Adikari, M.; Parekh, H. K.; Simpkins, H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother. Pharmacol. 2004, 54, 301-307.
42. Fukumoto, S.; Yamauchi, N.; Moriguchi, H.; Hippo, Y.; Watanabe, A.; Shibahara, J.; Taniguchi, H.; Ishikawa, S.; Ito, H.; Yamamoto, S.; Iwanari, H.; Hironaka, M.; Ishikawa, Y.; Niki, T.; Sohara, Y.; Kodama, T.; Nishimura, M,; Fukayama, M.; Dosaka-Akita, H.; Aburatani, H. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 2005, 11, 1776-1785.
43. Martin, H. J.; Breyer-Pfaff, U.; Wsol, V.; Venz, S.; Block, S.; Maser, E. Purification and characterization of akrlblO from human liver: role in carbonyl reduction of xenobiotics. Drug Metab. Dispos. 2006, 34, 464-470.
44. Cao, D.; Fan, S. T.; Chung, S. S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 1998, 273, 11429-11435.
45. Penning, T. M. AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin. Cancer Res. 2005, 11, 1687-1690.
46. Chang, C. L.; Lao-Sirieix, P.: Save, V.; De La Cueva Mendez, G.; Laskey, R.; Fitzgerald, R. C. Retinoic acid induced glandular differentiation of the oesophagus. Gut 2007, 56, 906-917.
47. Das, B.; Tao, S. Z.; Mushnitsky, R.; Norin, A. J. Genetic identity and differential expression of p38.5 (Haymaker) in human malignant and nonmalignant cells. Int. J. Cancer 2001, 94, 800-806.
48. Crowley-Weber, C. L.; Payne, C. M.; Gleason-Guzman, M.; Watts, G. S.; Futscher, B.; Waltmire, C. N.; Crowley, C.; Dvorakova, K.; Bernstein, C; Craven, M.; Garewal, H.; Bernstein, H. Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis 2002, 23, 2063-2080.
49. Katakura, H.; Takenaka, K.; Nakagawa, M.; Sonobe, M.; Adachi, M.; Ito, S.; Wada, H.; Tanaka, F. Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC). Maspin in NSCLC. Lung Cancer 2006, 51, 323-328.
50. Camby, I.; Le Mercier, M.; Lefranc, F.; Kiss, R. Galectin-1: a small protein with major functions. Glycobiology 2006, 16, 137R-157R.
51. Das, B.; Mondragon, M. O.; Tao, S. Z.; Norin, A. J. Preferential interaction of a novel tumor surface protein (p38.5) with naive natural killer cells. J. Exp. Med. 1997, 185, 1735-1742.
52. Pfanner, N.; Chacinska, A. The mitochondrial import machinery: preprotein-conducting channels with binding sites for prese-quences. Biochim. Biophys. Acta 2002, 1592, 15-24.
53. Liaudet-Coopman, E.; Beaujouin, M.; Derocq, D.; Garcia, M.; Glondu-Lassis, M.; Laurent-Matha, V.,' Prebois, C; Rochefort, H.; Vignon, F. Cathepsin D: newly discovered functions of a longstanding aspartic protease in cancer and apoptosis. Cancer Lett. 2005, 237, 167-179.
54. Bailey, C. M.; Khalkhali-Ellis, Z.; Seftor, E. A.; Hendrix, M. J. Biological functions of maspin. J. Cell Physiol. 2006, 209, 617-624.
55. Bamburg, J. R.; Wiggan, O. P. ADF/cofilin and actin dynamics in disease. Trends Cell Biol. 2002, 12, 598-605.
56. Agnihotri, G.; Liu, H. W. Enoyl-CoA hydratasekbpr reaction, mechanism, and inhibition. Bioorg. Med. Chem. 2003, 11, 9-20.
57. Stolz, A.; Rahimi-Kiani, M.; Ameis, D.; Chan, E.; Ronk, M.; Shively, J. E. Molecular structure of rat hepatic 3 alpha-hydroxysteroid dehydrogenase. A member of the oxidoreductase gene family. J. Biol. Chem. 1991, 266, 15253-15257.
58. Tait, J. F.; Frankenberry, D. A.; Miao, C. H.; Killary, A. M.; Adler, D. A.; Disteche, C. M. Chromosomal localization of the human annexin III (ANX3) gene. Genomics 1991, 10, 441-448.
59. Drusco, A.; Zanesi, N.; Roldo, C; Trapasso, F.; Farber, J. L.; Fong, L. Y.; Croce, C. M. Knockout mice reveal a tumor suppressor function for Testin. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 10947-10951.